Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose crossover study of inhaled PF-03635659 in moderate COPD
2009-014540-11Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of PF-03635659 in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Pfizer. Primary endpoints: Bronchodilatory trough effect and Benchmark against tiotropium. Started Nov 2009; status: completed.
02
Drugs
PF-03635659
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-014540-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014540-11.